Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Dosing Is Achilles Heel For Pfizer’s First Candidate
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.
You may also be interested in...
The obesity market offers big revenue potential but Pfizer’s oral GLP-1 candidate is currently dosed twice daily.
Chief development officer William Pao oversees Pfizer’s clinical pipeline. He joined the company from Roche following a career in academia, and after his first year at Pfizer talked to Scrip about the transition to late-stage drug development.
Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau.